FNY Investment Advisers’s Neuphoria Therapeutics NEUP Stock Holding History

FNY Investment Advisers’s Portfolio NEUP Stock Details NEUP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Hold	26,500	–	–	0.04%	307
2026 Q1	$107K	Hold	26,500	–	–	0.05%	269
2025 Q4	$102K	Buy	+26,500	New	+$188K	0.03%	340
2023 Q4	–	Sell	-177	Closed	-$5K	–	804
2023 Q3	$5K	Buy	+177	New	+$3.81K	﹤0.01%	465

Other funds holding NEUP

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

FNY Investment Advisers's NEUP Position: Q2 2026 in Review

FNY Investment Advisers held its Neuphoria Therapeutics (NEUP) position steady in Q2 2026 at 26,500 shares worth $115K. The position accounts for 0.04% of the portfolio, ranked #307.

FNY Investment Advisers first reported a position in NEUP in Q3 2023 and has held it in 4 quarters since. 3 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

FNY Investment Advisers held 26,500 shares of Neuphoria Therapeutics worth $115K as of Q2 2026.
FNY Investment Advisers left its Neuphoria Therapeutics share count unchanged in Q2 2026.
Neuphoria Therapeutics made up 0.04% of FNY Investment Advisers's portfolio in Q2 2026, its #307 holding.
FNY Investment Advisers first reported a position in Neuphoria Therapeutics in Q3 2023 and has held it in 4 quarters since.
3 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.